Shanghai Fochon Pharmaceutical Co., Ltd.

Fochon Pharmaceuticals, Ltd.

Chinese Academy of Sciences

Chongqing Fochon Pharmaceutical Co., Ltd.

Fochon Biosciences, Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Fochon Pharmaceutical Co., Ltd.

Haohan Tan

Weibo Wang

Xingdong Zhao

Xianlong Wang

Zhifang Chen

Jing Sun

Yanxin Liu

Rui Tan

Zuwen Zhou

Lihua Jiang

Zhifu Li

Qihong Liu

Hongbin Liu

Weipeng Zhang

Tongshuang Li

Ling Chen

Huajie Zhang

Yue Rong

Qiang Tian

Min Lin

Chengxi He

Lijun Yang

Zongyao Zou

Bin Liu

Li Linghu

Kai Ran

Jian Ding

Meiyu Geng

Jing Ai

Xia Peng

Fanxin Zeng

Shu Lin

Quan Yuan

Hailong Shi

Bo Fang

Yuwei Gao

Jiemin Fu

Yunling Wang

Chuiliang Yu

Hong Fu

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Apoptosis-inducing agents

Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Macrocyclic compounds as TRK kinases inhibitors

Provided are certain TRK inhibitors of formula (I): pharmaceutical compositions thereof, and methods of use thereof.

Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase

Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders. 

Compounds as BLC-2-selective apoptosis-inducing agents

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Indolizine derivatives, composition and methods of use

Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors

Provided are certain CDK4/6 inhibitors with the structure of formula (I), pharmaceutical compositions thereof, and methods of use therefor. The compounds are of the class of pyrimidin-2 amine derivatives, useful for the treatment of hyper-proliferative diseases. 

Certain protein kinase inhibitor

Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof. 

Certain protein kinase inhibitors

Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Disclosed herein are protein kinase inhibitors, more particularly novel pyrimidine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Growing community of inventors

Chongqing, China

Haohan Tan